Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients

Drug and Alcohol Dependence

Volumn 157, Issue , 2015, Pages 184-187

  McDonell, Michael G ^a   Skalisky, Jordan ^a   Leickly, Emily ^c   McPherson, Sterling ^a,b   Battalio, Samuel ^c   Nepom, Jenny R ^a   Srebnik, Debra ^c   Roll, John ^a,b   Ries, Richard K ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Providence Medical Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alcohol biomarkers; Assessment of cut off; Ethyl glucuronide in urine; Heavy drinking

Indexed keywords

ETHYL GLUCURONIDE; BIOLOGICAL MARKER; GLUCURONIC ACID;

ADULT; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; FALSE POSITIVE RESULT; FEMALE; HEAVY DRINKING; HUMAN; IMMUNOASSAY; LIGHT DRINKING; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT; PRIORITY JOURNAL; SELF REPORT; URINALYSIS; URINE LEVEL; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SPECTROPHOTOMETRY; STANDARD; STANDARDS; SUBSTANCE ABUSE; URINE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BIOMARKERS; FEMALE; GLUCURONATES; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; OUTPATIENTS; REFERENCE STANDARDS; SELF REPORT; SPECTROPHOTOMETRY; SUBSTANCE ABUSE DETECTION;

EID: 84950975737     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.10.004     Document Type: Article

References (18)

1. American Psychiatric Association DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Press Inc., Washington, DC. fourth, text revision ed.
2. Babor T.F., Steinberg K., Anton R., Del Boca F. Talk is cheap: measuring drinking outcomes in clinical trials. J. Stud. Alcohol 2000, 61:55-63.
3. Dahl H., Carlsson A.V., Hillgren K., Helander A. Urinary ethyl glucuronide and ethyl sulfate testing for detection of recent drinking in an outpatient treatment program for alcohol and drug dependence. Alcohol Alcohol. 2011, 46:278-282.
4. Del Boca F.K., Noll J.A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000, 3(95 Suppl.):S347-S360.
5. Donovan D.M., Bigelow G.E., Brigham G.S., Carroll K.M., Cohen A.J., Gardin J.G., Hamilton J.A., Huestis M.A., Hughes J.R., Lindblad R., Marlatt G.A., Preston K.L., Selzer J.A., Somoza E.C., Wells E.A. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012, 107:694-708. 10.1111/j.1360-0443.2011.03473.x.
6. FDA Alcoholism: Developing Drugs for Treatment Guidance for Industry 2015, Food and Drug Administration, Rockville, MD, Retrieved from 〈http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm433618.pdf〉.
7. Hegstad S., Helland A., Hagemann C., Michelsen L., Spigset O. EtG/EtS in urine from sexual assault victims determined by UPLC-MS-MS. J. Anal. Toxicol. 2013, 37:227-232.
8. IBM IBM SPSS Statistics for Windows (Version 19.0) 2010, IBM Corp., Armonk, NY.
9. Jatlow P., O'Malley S.S. Clinical (nonforensic) application of ethyl glucuronide measurement: are we ready?. Alcohol. Clin. Exp. Res. 2010, 34:968-975. 10.1111/j.1530-0277.2010.01171.x.
10. Jatlow P.I., Agro A., Wu R., Nadim H., Toll B.A., Ralevski E., Nogueira C., Shi J., Dziura J.D., Perakis I.L., O'Malley S.S. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol. Clin. Exp. Res. 2014, 10.1111/acer.12407.
11. Langenbucher J., Merrill J. The validity of self-reported cost events by substance abusers, limits, liabilities, and future directions. Eval. Rev. 2001, 25:184-210.
12. Leickly E., McDonell M.G., Vilardaga R., Angelo F.A., Lowe J.M., McPherson S., Srebnik s., Roll J.M., Ries R.K. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am. J. Drug Alcohol Abuse 2015, 41:246-250. 10.3109/00952990.2015.1011743.
13. Litten R.Z., Bradley A.M., Moss H.B. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol. Clin. Exp. Res. 2010, 34:955-967. 10.1111/j.1530-0277.2010.01170.x.
14. Lowe J., McDonell M., Leickly E., Angelo F., Vilardaga R., McPherson S., Srebnik D., Roll J., Ries R. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol. Clin. Exp. Res. 2015, 39:905-910. 10.1111/Acer.12699.
15. SAMHSA The Role of Biomarkers in the Treatment of Alcohol Use Disorders, 2012 Revision 2012, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD.
16. Sobell L.C., Sobell M.B. Alcohol Timeline Followback (TLFB), Handbook of Psychiatric Measures 2000, 477-479. American Psychiatric Association, Washington, DC.
17. Stewart S.H., Koch D.G., Burgess D.M., Willner I.R., Reuben A. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol. Clin. Exp. Res. 2013, 37:150-155.
18. Wurst F.M., Kempter C., Metzger J., Seidl S., Alt A. Ethyl glucuronide: a marker of recent alcohol consumption with clinical and forensic implications. Alcohol 2000, 20:111-116.